Your browser doesn't support javascript.
loading
Heterogeneity of Benefit from Earlier Time-to-Antibiotics for Sepsis.
Hechtman, Rachel K; Kipnis, Patricia; Cano, Jennifer; Seelye, Sarah; Liu, Vincent X; Prescott, Hallie C.
Afiliación
  • Hechtman RK; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
  • Kipnis P; Division of Research, Kaiser Permanente, Oakland, California; and.
  • Cano J; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.
  • Seelye S; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.
  • Liu VX; Division of Research, Kaiser Permanente, Oakland, California; and.
  • Prescott HC; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Am J Respir Crit Care Med ; 209(7): 852-860, 2024 04 01.
Article en En | MEDLINE | ID: mdl-38261986
ABSTRACT
Rationale Shorter time-to-antibiotics improves survival from sepsis, particularly among patients in shock. There may be other subgroups for whom faster antibiotics are particularly beneficial.

Objectives:

Identify patient characteristics associated with greater benefit from shorter time-to-antibiotics.

Methods:

Observational cohort study of patients hospitalized with community-onset sepsis at 173 hospitals and treated with antimicrobials within 12 hours. We used three approaches to evaluate heterogeneity of benefit from shorter time-to-antibiotics 1) conditional average treatment effects of shorter (⩽3 h) versus longer (>3-12 h) time-to-antibiotics on 30-day mortality using multivariable Poisson regression; 2) causal forest to identify characteristics associated with greatest benefit from shorter time-to-antibiotics; and 3) logistic regression with time-to-antibiotics modeled as a spline.Measurements and Main

Results:

Among 273,255 patients with community-onset sepsis, 131,094 (48.0%) received antibiotics within 3 hours. In Poisson models, shorter time-to-antibiotics was associated with greater absolute mortality reduction among patients with metastatic cancer (5.0% [95% confidence interval; CI 4.3-5.7] vs. 0.4% [95% CI 0.2-0.6] for patients without cancer, P < 0.001); patients with shock (7.0% [95% CI 5.8-8.2%] vs. 2.8% [95% CI 2.7-3.5%] for patients without shock, P = 0.005); and patients with more acute organ dysfunctions (4.8% [95% CI 3.9-5.6%] for three or more dysfunctions vs. 0.5% [95% CI 0.3-0.8] for one dysfunction, P < 0.001). In causal forest, metastatic cancer and shock were associated with greatest benefit from shorter time-to-antibiotics. Spline analysis confirmed differential nonlinear associations of time-to-antibiotics with mortality in patients with metastatic cancer and shock.

Conclusions:

In patients with community-onset sepsis, the mortality benefit of shorter time-to-antibiotics varied by patient characteristics. These findings suggest that shorter time-to-antibiotics for sepsis is particularly important among patients with cancer and/or shock.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Choque Séptico / Sepsis / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Choque Séptico / Sepsis / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2024 Tipo del documento: Article